Divalproex Sodium Extended-release
Product Images NDC 53808-1061

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium Extended-release (NDC 53808-1061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 500mg (Divalproex)

Label for Divalproex Sodium 500 mg Extended-Release tablets, package of 30, from State of Florida DOH Central Pharmacy. Label includes lot number, expiration date of February 8, 2015, and a barcode. Marked as prescription only and includes DOH lot information and location in Tallahassee, FL.*

FDA Label Image

Chemical Structure Of Divalproex Sodium (Depakote Er 01)

Chemical structure of the active ingredient divalproex sodium, showing the sodium salt form of valproic acid connected to its molecular groups.*

FDA Label Image

Figure-1 (Img 0400)

A comparative response curve graph showing the percentage reduction in CPS rate for patients treated with valproate versus placebo. The x-axis represents the percentage of patients, and the y-axis indicates the percent reduction in CPS rate, with improvement above zero and worsening below zero. The graph displays valproate (solid line) achieving greater improvement than placebo (dashed line).*

FDA Label Image

Figure-2 (Img 0401)

A cumulative frequency plot depicting percentage reduction in complex partial seizure (CPS) rate versus percentage of patients treated with high dose and low dose valproate. The vertical axis shows improvement and worsening in seizure rate, while the horizontal axis represents patient percentage from 0 to 100. High dose valproate is shown with a solid line and low dose valproate with a dashed line.*

FDA Label Image

Figure-3 (Img 0402)

A bar chart comparing placebo to Divalproex sodium extended-release tablets, showing higher value for the Divalproex group (1.2) compared to placebo (0.6), with a p-value of 0.006 indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.